Drugs / RC98
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05514158 | Sep 2022 → May 2024 | gastric cancer | RemeGen Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04190823 | Mar 2020 → Dec 2023 | cancer | RemeGen Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC98 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04190823 ↗ |
| Known as | RC98 for Injection | “RC98 for Injection” NCT04190823 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized IgG1 monoclonal antibody” NCT05514158 ↗ |
| Target | CD274 | “targeting programmed cell death-Ligand 1 (PD-L1)” NCT05514158 ↗ |